Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company situated in Durham, North Carolina. The company employs 27 people. Atsena Therapeutics specializes in developing innovative treatments for inherited forms of blindness. Their current clinical programs include ATSN-201 for X-linked retinoschisis (XLRS) and ATSN-101 for Leber congenital amaurosis (LCA1). ATSN-201 utilizes a novel spreading capsid AAV.SPR, and the company is preparing to launch The Lighthouse Study, a Phase I/II clinical trial to evaluate its effectiveness in treating XLRS. ATSN-301, another proprietary asset, is a dual AAV vector-based gene therapy aimed at preventing blindness caused by MYO7A-associated Usher syndrome (USH1B). Atsena Therapeutics has demonstrated promising results with ATSN-101, showing that it is well-tolerated and produces clinically meaningful improvements in vision six months after treatment in patients with LCA1. For more information, visit www.atsenatx.com.